Close

Anti-EGFR (Cetuximab) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-LC127)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of NK cells to target human EGFR. The NK cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFR antibody linked to 4-1BB (CD137) and CD3ζ signaling domain. And the vector product was designed for the treatment of melanoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • EGFR
  • Targeting Cell Type
  • NK cell
  • Targeting Diseases
  • Melanoma
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • Cetuximab
  • Host
  • Human
  • Target Species
  • Human
  • Gene Name
  • Epidermal Growth Factor Receptor
  • Synonyms
  • EGFR;EGFR; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor; Receptor Tyrosine-Protein Kinase ErbB-1; Erb-B2 Receptor Tyrosine Kinase 1; Proto-Oncogene C-ErbB-1; EC 2.7.10.1; ERBB1; ERBB; HER1; Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog); Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian);

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data FCM

Fig.1 Surface expression of EGFR on osteosarcoma and Ewing's sarcoma cell lines was measured by flow cytometry using the anti-EGFR mAb cetuximab followed by the Alexa Fluor-647 goat anti-human IgG secondary antibody.

CAR Construction : Latest CAR Construction

Fig.1 Surface expression of EGFR on osteosarcoma and Ewing's sarcoma cell lines was measured by flow cytometry using the anti-EGFR mAb cetuximab followed by the Alexa Fluor-647 goat anti-human IgG secondary antibody.

EGFR is expressed on the surface of sarcoma cell lines

Pahl, J. H., Ruslan, S. E. N., Buddingh, E. P., Santos, S. J., Szuhai, K., Serra, M., ... & Lankester, A. C. (2012). Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward OsteosarcomaCetuximab Enhances NK Cell Killing of Sarcoma Cells. Clinical cancer research, 18(2), 432-441.

Complete CAR data FCM

Fig.2 HEK293T cells transfected with a CTL vector orthe two EGFR CAR expression vectors.

CAR Construction : Cetuximab scFv-28ζ Latest CAR Construction

Fig.2 HEK293T cells transfected with a CTL vector orthe two EGFR CAR expression vectors.

Two EGFR CAR expression vectors as described inawere stained with an APC-conjugated anti-human IgG-Fc antibody or a FITC-conjugatedanti-human IgG (Fab)2 antibody followed by flow cytometry analysis.

Xia, L., Zheng, Z. Z., Liu, J. Y., Chen, Y. J., Ding, J. C., Xia, N. S., ... & Liu, W. (2020). EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo. Clinical & translational immunology, 9(5), e1135.

Complete CAR data FCM

Fig.3 CTL T or EGFR CAR-T cells were incubated with MDA-MB-231 or MDA-MB-468 cells and stained with CD8-APC and CD69-PE or CD25-FITC followed by flow cytometry analysis.

CAR Construction : Cetuximab scFv-28ζ Latest CAR Construction

Fig.3 CTL T or EGFR CAR-T cells were incubated with MDA-MB-231 or MDA-MB-468 cells and stained with CD8-APC and CD69-PE or CD25-FITC followed by flow cytometry analysis.

Experiments were repeated three times, and representative histograms are shown.

Xia, L., Zheng, Z. Z., Liu, J. Y., Chen, Y. J., Ding, J. C., Xia, N. S., ... & Liu, W. (2020). EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo. Clinical & translational immunology, 9(5), e1135.

Complete CAR data Cyt

Fig.4 EGFR CAR-T cells were incubated with MCF10A, MCF7, BT474, MDA-MB-468 or MDA-MB-231 cells at a ratio of 1:1 for the indicated durations followed by the cytotoxicity assay.

CAR Construction : Cetuximab scFv-28ζ Latest CAR Construction

Fig.4 EGFR CAR-T cells were incubated with MCF10A, MCF7, BT474, MDA-MB-468 or MDA-MB-231 cells at a ratio of 1:1 for the indicated durations followed by the cytotoxicity assay.

Data were obtained from three replicates and are presented as means.e.m..

Xia, L., Zheng, Z. Z., Liu, J. Y., Chen, Y. J., Ding, J. C., Xia, N. S., ... & Liu, W. (2020). EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo. Clinical & translational immunology, 9(5), e1135.

Complete CAR data FuncS

Fig.5 Tumor growth was monitored by using bioluminescence imaging for 20 days.

CAR Construction : Cetuximab scFv-28ζ Latest CAR Construction

Fig.5 Tumor growth was monitored by using bioluminescence imaging for 20 days.

Representative data of two independentexperiments are shown.

Xia, L., Zheng, Z. Z., Liu, J. Y., Chen, Y. J., Ding, J. C., Xia, N. S., ... & Liu, W. (2020). EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo. Clinical & translational immunology, 9(5), e1135.

Complete CAR data TCA

Fig.6 Primary T lymphocytes infected with EGFR CAR lentivirus (EGFR CAR-T) labelled with CFSE were incubated with or without MDA-MB-231 or MDA-MB-468 cells.

CAR Construction : Cetuximab scFv-28ζ Latest CAR Construction

Fig.6 Primary T lymphocytes infected with EGFR CAR lentivirus (EGFR CAR-T) labelled with CFSE were incubated with or without MDA-MB-231 or MDA-MB-468 cells.

Experiments were repeated three times, and representative histograms are shown.

Xia, L., Zheng, Z. Z., Liu, J. Y., Chen, Y. J., Ding, J. C., Xia, N. S., ... & Liu, W. (2020). EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo. Clinical & translational immunology, 9(5), e1135.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-EGFR (Cetuximab) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-LC127). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.